Literature DB >> 832037

Apparent resistance to hypotensive effect of clonidine.

L M Wing, J L Reid, D S Davies, H J Dargie, C T Dollery.   

Abstract

Clonidine failed to reduce the blood pressures of two patients with essential hypertension. On was given 5-4 mg/day and the other 6 mg/day, and their respective peak plasma clonidine concentrations were 26-2 ng/ml and 14-4 ng/ml. Several months after the end of clonidine treatment a single oral dose of 0-3 mg of clonidine produced maximum falls in blood pressure of 30/22 mm Hg and 88/41 mm Hg with peak plasma clonidine concentrations of 1-4 ng/ml and 0-9 ng/ml. Resistance to the hypotensive effect of high doses of clonidine may be due to stimulation of peripheral alpha-adrenoceptors causing vasoconstriction, which maintains a raised blood pressure.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 832037      PMCID: PMC1603915          DOI: 10.1136/bmj.1.6054.136

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  5 in total

1.  Clonidine overdose.

Authors:  S N Hunyor; K Bradstock; P J Somerville; N Lucas
Journal:  Br Med J       Date:  1975-10-04

2.  Clinical pharmacology and pharmacokinetics of clonidine.

Authors:  C T Dollery; D S Davies; G H Draffan; H J Dargie; C R Dean; J L Reid; R A Clare; S Murray
Journal:  Clin Pharmacol Ther       Date:  1976-01       Impact factor: 6.875

3.  Evidence for an alpha-sympathomimetic component in the effects of catapresan on vasomotor centres: antagonism by piperoxane.

Authors:  H Schmitt; S Fenard
Journal:  Eur J Pharmacol       Date:  1971       Impact factor: 4.432

4.  Central and peripheral alpha adrenergic activity of imidazoline derivatives.

Authors:  H S Boudier; G Smeets; G Brouwer; J van Rossum
Journal:  Life Sci       Date:  1974-09-01       Impact factor: 5.037

5.  Interactions between 2-(2,6-dichlorophenylamino)-2-imidazoline hydrochloride (St 155, Catapresan) and alpha-adrenergic blocking drugs.

Authors:  H Schmitt; H Schmitt
Journal:  Eur J Pharmacol       Date:  1970-01       Impact factor: 4.432

  5 in total
  9 in total

1.  Randomized clinical trial to compare the efficacy to improve the quality of surgical field of hypotensive anesthesia with clonidine or dexmedetomidine during functional endoscopic sinus surgery.

Authors:  Y Escamilla; A Cardesín; L Samara; S López; A Izquierdo; M Fradera; R Vives; M Bernal-Sprekelsen; Caridad Pontes
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-30       Impact factor: 2.503

2.  The Fourth Lilly Prize Lecture, University of Aberdeen, September 1980. The clinical pharmacology of clonidine and related central antihypertensive agents.

Authors:  J L Reid
Journal:  Br J Clin Pharmacol       Date:  1981-09       Impact factor: 4.335

3.  Effects of chromogranin A deficiency and excess in vivo: biphasic blood pressure and catecholamine responses.

Authors:  Sucheta M Vaingankar; Ying Li; Nilima Biswas; Jiaur Gayen; Sonia Choksi; Fangwen Rao; Michael G Ziegler; Sushil K Mahata; Daniel T O'Connor
Journal:  J Hypertens       Date:  2010-04       Impact factor: 4.844

4.  Relationship between the cardiovascular effects and steady-state kinetics of clonidine in hypertension. Demonstration of a therapeutic window in man.

Authors:  M Frisk-Holmberg; L Paalzow; L Wibell
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

5.  Relationship between plasma concentrations of clonidine and mean arterial pressure during an accidental clonidine overdose.

Authors:  L E Domino; S E Domino; M S Stockstill
Journal:  Br J Clin Pharmacol       Date:  1986-01       Impact factor: 4.335

6.  Long-term clonidine effects on autonomic function in essential hypertensive man.

Authors:  I M Cohen; D T O'Connor; R A Preston; R A Stone
Journal:  Eur J Clin Pharmacol       Date:  1981-01       Impact factor: 2.953

7.  Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients.

Authors:  M Frisk-Holmberg; P O Edlund; L Paalzow
Journal:  Br J Clin Pharmacol       Date:  1978-09       Impact factor: 4.335

8.  Clinical Practice: Should we Radically Alter our Sedation of Critical Care Patients, Especially Given the COVID-19 Pandemics?

Authors:  D Longrois; F Petitjeans; O Simonet; M de Kock; M Belliveau; C Pichot; Th Lieutaud; M Ghignone; L Quintin
Journal:  Rom J Anaesth Intensive Care       Date:  2021-01-04

9.  How should dexmedetomidine and clonidine be prescribed in the critical care setting?

Authors:  Dan Longrois; Fabrice Petitjeans; Olivier Simonet; Marc de Kock; Marc Belliveau; Cyrille Pichot; Thomas Lieutaud; Marco Ghignone; Luc Quintin
Journal:  Rev Bras Ter Intensiva       Date:  2022-01-24
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.